Merck KGaA’s BTK inhibitor had been hailed as the first to show activity in multiple sclerosis, but full clinical results cast doubt on this claim.
Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all…
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
The company needed a hit in its spine trial, and it claims to have got one.
Achieve Life Sciences gets a reality check despite largely positive smoking cessation data.
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
Lilly is still trying to find a therapeutic window following gastrointestinal issues with its brightest pipeline hope, the GIP/GLP1 agonist tirzepatide.
Protagonist Therapeutics and Pfizer will soon get an idea of their respective chances in beta-thalassaemia and Duchenne muscular dystrophy.
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.